H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CAPR stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including Capricor Therapeutics’ strong financial position and its ongoing efforts to address regulatory challenges. Despite the recent Complete Response Letter (CRL) from the FDA regarding deramiocel’s Biologics License Application (BLA), the company remains financially robust with a cash runway extending into late 2026. This financial stability provides Capricor with the necessary resources to continue navigating the regulatory landscape.
Additionally, Capricor is actively engaging with the FDA to resolve outstanding issues, including a Type A meeting to discuss the CRL. The company is also poised to supplement its BLA with data from the HOPE-3 trial, which could bolster its case for approval. The trial’s potential change in primary endpoint to Left Ventricular Ejection Fraction (LVEF) may further enhance the program’s prospects. These strategic initiatives, alongside the anticipation of upcoming trial results, underpin Pantginis’s optimistic outlook on Capricor’s future performance.
According to TipRanks, Pantginis is an analyst with an average return of -14.3% and a 33.67% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and Cytokinetics.
In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $12.00 price target.